Interestingly, the nature of the various IDH substitutions differs among the cancer types, i.e., IDH1 is more frequently mutated in solid tumours, while IDH2 is mainly mutated in some blood cancers. This evidence concerns the gene IDH2 and hematopoietic and lymphoid system neoplasm.